



The Golden West Chapter of The ALS Association fueled a significant number of research innovations, advancements in drug development and clinical trials, and new collaborations designed to accelerate the pace of discovery. These important milestones and promising progress in the search for effective treatments and cures for ALS are made possible by your support.


\$44M



The ALS Association is providing funding for **121 active projects in 12 countries (including the United States) with \$44 million currently committed** to research as of November 1, 2022.



The FDA approved an oral formulation of Mitsubishi Tanabe Pharma America, Inc's (MTPA) drug, **edaravone, allowing for greater ease of use and making the drug accessible to more people.**



Joined by Mitsubishi Tanabe Pharma America this year, our Industry Partner Consortium, launched with strong support from CNS and Cytokinetics, is **deeply committed to supporting the ALS community, scientific discovery, collaboration, and investment in therapies** for neurodegenerative diseases including ALS.

\$3.6M



The ALS Association funded **\$3.6 million to four interventional trials** through our new Clinical Trial Awards program, which seeks to stimulate the development of therapeutics for ALS by funding early-stage clinical trials that generate data on important issues like safety, dosing, and biomarkers.



Cytokinetics and The ALS Association announced **a new release of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database updated with clinical data from Cytokinetics' completed clinical trials in ALS** to further research, understanding, and potential breakthroughs for people living with the disease. The PRO-ACT database, which is sponsored by the ALS Association and managed by The Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital, houses the largest ALS clinical trials dataset, containing nearly 11,000 ALS de-identified patient records from 23 completed clinical trials.



The FDA announced their approval of RELYVRIO (AMX0035). The drug has been shown to slow the progression of the disease and extend life by several months. The ALS Association funded the clinical trial and worked with additional ALS organizations to advocate for approval. Our Chapter honored Amylyx Pharmaceuticals Inc. with our 2021 Commitment to Cures Award.



The National Academies of Sciences, Engineering, and Medicine (NAS) announced a study on **accelerating the development of treatments and improving quality of life for people with ALS.**



Newly published data from Biogen, our Chapter's 2020 Commitment to Cures honoree, showed that earlier intervention with the **antisense drug tofersen could be effective at slowing disease progression.** Golden West Chapter Advisory Trustee, Dr. Richard Smith, Director of the Center for Neurologic Study, had a foundational role in the development of this drug. The FDA is scheduled to decide on whether to approve tofersen by April 25, 2023.



To promote access to research opportunities, the Chapter increased communications about clinical trials available for people living with ALS. This was achieved through our monthly support group emails and e-Newsletters.



The Golden West Chapter **hosted the 12th annual California ALS Research Summit**, bringing together world renowned researchers, investigators, clinicians, biotech companies, government representatives, and advocates in ALS and related fields. The outcomes of their efforts were presented to the public at our virtual educational "ASK ME" event - available to view online.

Your support makes a difference. It is only together that we will defeat ALS.